Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

A Phase IIa, randomized, double-blind, placebo-controlled study to evaluate multiple doses of GLPG2222 in subjects with Cystic Fibrosis who are homozygous for the F508del mutation


Collapse Overview 
Collapse sponsor award id
GLPG2222-CL


Collapse Biography 

Collapse Time 
Collapse start date
2017-07-05